Solid Biosciences Inc. (SLDB)

Solid Biosciences' stock has increased by 28.9% since the beginning of 2026, trading at $7.27 as of May 9, 2026. On May 7, 2026, Solid Biosciences dosed the first participant in its Phase 3 IMPACT DUCHENNE clinical trial for SGT-003. The company announced inducement grants of restricted stock units to newly hired employees on May 1, 2026, and March 2, 2026. Solid Biosciences received European Commission Orphan Drug Designation for SGT-003 for Duchenne Muscular Dystrophy around April 2026. In March 2026, the company completed a $240 million private placement, extending its cash runway into the first half of 2028. Positive interim data from the Phase 1/2 INSPIRE DUCHENNE trial for SGT-003 was reported in March 2026, showing robust microdystrophin expression and generally favorable safety. The stock price has shown volatility, with a 13% average weekly change over the past three months. Technical analysis indicators in late April and early May 2026 suggested a downward trend, with the stock moving below its 50-day moving average. Shareholder dilution has been identified as a minor risk, with a 27% increase in shares outstanding in the past year.

For Solid Biosciences, Inc., demand seasonality is not a significant factor due to its products being largely in clinical development. The company's "Seasonality Score" of 50 indicates it is "fair valued in the industry" and describes predictable price changes around the same period each year. The demand for its gene therapy candidates is driven by the prevalence of the rare neuromuscular and cardiac diseases they aim to treat, rather than seasonal fluctuations.

Solid Biosciences, Inc. (SLDB) is a life sciences company focused on developing precision genetic medicines for rare neuromuscular and cardiac diseases, operating within the Healthcare sector. Its major product candidates include SGT-003 for DMD in Phase 1/2 and Phase 3 trials, SGT-212 for FA in Phase 1b trial, SGT-501 for CPVT in preclinical and Phase 1b stages, SGT-601 for TNNT2-mediated dilated cardiomyopathy in preclinical phase, SGT-401 for BAG3-mediated dilated cardiomyopathy in preclinical phase and SGT-701 for rare inherited disease characterized by mutations in the RBM20 gene, in discovery phase. The company also develops innovative libraries of genetic regulators and other enabling technologies to impact gene therapy delivery.

Solid Biosciences Inc. is headquartered in Charlestown, Massachusetts, United States. The company develops therapies in the United States and has plans for international clinical trial application submissions.

Solid Biosciences' brand reputation has been positively influenced by FDA Fast Track Designation for SGT-501 for CPVT and Rare Pediatric Disease Designation for SGT-212 for Friedreich's Ataxia. SGT-003 also received Innovation Passport Designation under the UK Innovative Licensing and Access Pathway and European Commission Orphan Drug Designation. Positive interim clinical updates from the Phase 1/2 INSPIRE DUCHENNE trial for SGT-003 have contributed to a favorable perception of its pipeline. The initiation of the Phase 3 IMPACT DUCHENNE clinical trial for SGT-003 further underscores progress in its lead program. A potential negative factor impacting reputation, though noted as a minor risk, is shareholder dilution due to an increase in shares outstanding.

Solid Biosciences Inc. has a mixed ownership structure, including institutional, insider, and retail investors. As of May 5, 2026, there were 126 institutional owners holding a total of 79,962,057 shares. Major institutional shareholders include Perceptive Advisors Llc, Bain Capital Life Sciences Investors, LLC, Siren, L.L.C., Vestal Point Capital, LP, Ra Capital Management, L.p., BlackRock, Inc., and Vanguard Group Inc. Approximately 13.16% of the company's stock is owned by insiders. Retail investors hold a significant portion, with approximately 69.91% of the stock owned by public companies and individual investors.